PO:05:136 Measurement of kidney disease in a novel treatment response measure for systemic lupus erythematosus clinical trials

induced a sustained anti-dsDNA decline, and Rituximab showed less consistent improvement.Hematologic values (hemoglobin, lymphocytes, platelets) remained generally stable across all groups.Together, these data highlight distinct response profiles that may inform individualized treatment strategies.Conclusions In this real-world SLE cohort, biologic persistence was comparable, with most discontinuations due to infections or inefficacy.Treatment choice reflected phenotype-Belimumab in renal disease, Anifrolumab in cutaneous/articular, and Rituximab in severe hematologic/neuropsychiatric cases-while serologic responses diverged: Anifrolumab improved C3, Belimumab reduced anti-dsDNA, and Rituximab was less consistent.These findings highlight the need to tailor biologic therapy according to patient profile and serologic trajectory.